We speculate that bispecific CD19/22 CAR T cells are able to be stimulated by many more antigens in PB and have better antitumor activity than CD19 CAR T cells, because of the bispecific CD19/22 CAR T cells could not only recognize and kill CD19+ tumor cells but also recognize CD22+ and CD19+CD22+ tumor cells. The gene discussed is CD22; the disease is neoplasm.